Company · CIK 0001974640 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Apogee Therapeutics, Inc. · APGE
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 DForm 4 → | Sep 3, 5:30 pm EDT | Fairmount Funds Management LLC +3Director | 443,187 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Mark C. McKennaDirector | 20,000 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | William A Jones Jr.Director | 34,824 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Jennifer A. FoxDirector | 34,824 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Jane HendersonChief Financial Officer | 158,371 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 920,941 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Nimish P ShahDirector | 1,750,000 | $135.11 | $236,442,500 | 0 | — | |
| Sep 2, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Carl DambkowskiChief Medical Officer | 168,498 | $135.06 | $185,708 | 0 | — | |
| Aug 7, 2026 MForm 4 → | Aug 11, 4:30 pm EDT | Fairmount Funds Management LLC +3Director | 42,208 | $23.60 | $995,971 | 340,855 | — | |
| Aug 5, 2026 SForm 4 → | Aug 7, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 5,500 | $134.17 | $737,935 | 168,498 | −3.16% | 10b5-1 |
| Aug 5, 2026 MForm 4 → | Aug 7, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | $22.86 | $94,298 | 173,998 | — | 10b5-1 |
| Jul 24, 2026 GForm 4 → | Jul 24, 8:00 pm EDT | Jane HendersonChief Financial Officer | 15,000 | — | — | 158,371 | — | |
| Jul 14, 2026 GForm 4 → | Jul 16, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 8,000 | — | — | 169,873 | — | |
| Jul 10, 2026 GForm 4 → | Jul 10, 8:00 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 75,046 | — | — | 920,941 | — | 10b5-1 |
| Jul 8, 2026 SForm 4 → | Jul 10, 8:00 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 20,000 | $133.63 | $2,672,600 | 995,987 | −1.97% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 2, 8:13 pm EDT | Carl DambkowskiChief Medical Officer | 5,500 | $132.74 | $730,070 | 177,873 | −3.00% | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 8:13 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | $22.86 | $94,298 | 183,373 | — | 10b5-1 |
| Jun 22, 2026 SForm 4 → | Jun 24, 8:01 pm EDT | Carl DambkowskiChief Medical Officer | 26,400 | $132.60 | $3,500,640 | 179,248 | −12.8% | 10b5-1 |
| Jun 22, 2026 SForm 4 → | Jun 24, 8:00 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 80,000 | $132.54 | $10,603,200 | 1,015,987 | −7.30% | 10b5-1 |
| Jun 10, 2026 SForm 4 → | Jun 12, 5:05 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 20,000 | $83.38 | $1,667,622 | 1,095,987 | −1.79% | 10b5-1 |
| Jun 3, 2026 SForm 4 → | Jun 5, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 5,500 | $78.71 | $432,905 | 205,648 | −2.60% | 10b5-1 |
| Jun 3, 2026 MForm 4 → | Jun 5, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | $22.86 | $94,298 | 211,148 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 DForm 4 → | Sep 3, 5:30 pm EDT | Fairmount Funds Management LLC +3Director | 6,823,567 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Mark C. McKennaDirector | 182,488 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | William A Jones Jr.Director | 32,488 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Carl DambkowskiChief Medical Officer | 319,317 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Jennifer A. FoxDirector | 32,488 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Jane HendersonChief Financial Officer | 383,997 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Lisa BollingerDirector | 48,780 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Michael Thomas HendersonChief Executive Officer, Director | 997,064 | — | — | 0 | — | |
| Sep 3, 2026 DForm 4 → | Sep 3, 4:39 pm EDT | Nimish P ShahDirector | 7,189,420 | $135.11 | $911,090,100 | 0 | — | |
| Aug 7, 2026 MForm 4 → | Aug 11, 4:30 pm EDT | Fairmount Funds Management LLC +3Director | 42,208 | — | — | 0 | — | |
| Aug 5, 2026 MForm 4 → | Aug 7, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | — | — | 110,665 | — | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 8:13 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | — | — | 114,790 | — | 10b5-1 |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:04 pm EDT | Fairmount Funds Management LLC +1Director | 7,657 | — | — | 7,657 | — | |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:03 pm EDT | Nimish P ShahDirector | 7,657 | — | — | 7,657 | — | |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:03 pm EDT | Mark C. McKennaDirector | 7,657 | — | — | 7,657 | — | |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:02 pm EDT | William A Jones Jr.Director | 7,657 | — | — | 7,657 | — | |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:01 pm EDT | Jennifer A. FoxDirector | 7,657 | — | — | 7,657 | — | |
| Jun 9, 2026 AForm 4 → | Jun 11, 8:00 pm EDT | Lisa BollingerDirector | 7,657 | — | — | 7,657 | — | |
| Jun 3, 2026 MForm 4 → | Jun 5, 8:00 pm EDT | Carl DambkowskiChief Medical Officer | 4,125 | — | — | 118,915 | — | 10b5-1 |